NURS6630 Psychopharmacology Final Exam: Questions
with Verified Correct Answers | Walden University
(2026/2027 Edition)
SUBTITLE:
50 Exam Questions with Answers & Detailed Rationales
PREPARED FOR:
[NURS 6630 Psychopharmacology - Walden University Final Examination]
DOCUMENT INCLUDES:
● Exam-style questions
● Correct answers
● Detailed rationales
● Key topics covered
TOPICS COVERED:
● Neurotransmitter Systems & Receptor Pharmacology
● Pharmacokinetics, Pharmacodynamics & Pharmacogenomics
● Antidepressants (SSRIs, SNRIs, TCAs, MAOIs, Atypical)
● Antipsychotics (Typical & Atypical)
● Mood Stabilizers (Lithium, Anticonvulsants)
● Anxiolytics, Hypnotics & Sedatives
● ADHD Pharmacotherapy
● Substance Use Disorder Treatments & Antidementia Agents
● Special Populations (Pediatrics, Geriatrics, Pregnancy)
● Adverse Effects, Drug Interactions, Monitoring & Black Box Warnings
PURPOSE:
This comprehensive final exam prep guide is designed to help NURS 6630 students
master psychopharmacological principles, understand medication mechanisms and
management, and confidently prepare for the Walden University Final Examination.
,SECTION 1: NEUROTRANSMITTER SYSTEMS & RECEPTOR PHARMACOLOGY
Question 1
A 28-year-old patient with depression is started on an SSRI. The PMHNP explains that
the primary mechanism of action involves blockade of the serotonin transporter (SERT)
at the presynaptic membrane. This action ultimately leads to which downstream effect?
A. Immediate increase in postsynaptic serotonin receptor sensitivity
B. Downregulation of 5-HT1A autoreceptors over 2-4 weeks
C. Direct agonism of D2 receptors in the mesolimbic pathway
D. Blockade of NMDA glutamate receptors in the hippocampus
Correct Answer: B
Rationale: SSRIs block SERT, increasing synaptic serotonin concentrations. Initially,
5-HT1A autoreceptors detect increased serotonin and reduce neuronal firing. Over 2-4
weeks, these autoreceptors downregulate and desensitize, allowing enhanced serotonin
neurotransmission—this delayed mechanism explains the characteristic 2-4 week
therapeutic lag. Option A is incorrect because postsynaptic receptors do not
immediately increase sensitivity; in fact, chronic SSRI use may lead to receptor
downregulation. Option C describes antipsychotic mechanisms. Option D describes
ketamine or memantine mechanisms.
Question 2
A patient taking haloperidol develops acute dystonia within 48 hours of initiation. The
PMHNP recognizes this adverse effect is due to antagonism of which receptor system?
A. 5-HT2A receptors in the prefrontal cortex
B. D2 receptors in the nigrostriatal pathway
C. H1 receptors in the tuberomammillary nucleus
D. M1 receptors in the basal ganglia
,Correct Answer: B
Rationale: Acute dystonia, along with akathisia and parkinsonism, are extrapyramidal
symptoms (EPS) caused by D2 receptor antagonism in the nigrostriatal pathway.
First-generation antipsychotics like haloperidol have high affinity for D2 receptors in this
pathway. Atypical antipsychotics have lower EPS liability due to 5-HT2A antagonism
offsetting D2 blockade. Option A is incorrect because 5-HT2A antagonism actually
reduces EPS. Option C explains sedation and weight gain. Option D explains
anticholinergic side effects.
Question 3
Which neurotransmitter system is primarily responsible for the sedating and
appetite-stimulating effects commonly seen with mirtazapine and quetiapine?
A. Dopamine D2 antagonism
B. Serotonin 5-HT2C antagonism
C. Histamine H1 antagonism
D. Norepinephrine alpha-1 antagonism
Correct Answer: C
Rationale: Histamine H1 receptor antagonism is the primary mechanism for sedation
and increased appetite/weight gain. Both mirtazapine and quetiapine are potent H1
blockers. While 5-HT2C antagonism (Option B) can increase appetite, H1 blockade is
the dominant mechanism for sedation and significantly contributes to weight gain.
Option D explains orthostatic hypotension and dizziness.
Question 4
The PMHNP is educating a patient about bupropion. Which statement accurately
describes its mechanism of action?
, A. It is a potent inhibitor of serotonin and norepinephrine reuptake
B. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) with minimal
serotonergic activity
C. It primarily blocks alpha-2 adrenergic autoreceptors
D. It is a selective serotonin reuptake inhibitor with high affinity for the 5-HT transporter
Correct Answer: B
Rationale: Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor
(NDRI). It inhibits the reuptake of norepinephrine and dopamine with minimal direct
effect on serotonin transporters. This mechanism explains why bupropion does not
cause sexual dysfunction or significant serotonergic side effects. Option A describes
SNRIs. Option C describes mirtazapine's indirect mechanism. Option D describes SSRIs.
Question 5
A patient with treatment-resistant schizophrenia is prescribed clozapine. The PMHNP
explains that clozapine's unique efficacy is attributed to its weak affinity for D2
receptors combined with potent antagonism at which receptor?
A. 5-HT1A
B. 5-HT2A
C. D1
D. GABA-A
Correct Answer: B
Rationale: Clozapine has low affinity for D2 receptors but high affinity for 5-HT2A,
5-HT2C, D1, D4, and various other receptors. The 5-HT2A/D2 ratio theory suggests that
potent 5-HT2A antagonism combined with weaker D2 antagonism contributes to its
unique efficacy in treatment-resistant schizophrenia and its lower propensity for
extrapyramidal symptoms. While clozapine also has 5-HT1A partial agonism, the
5-HT2A antagonism is central to its atypical pharmacological profile.
with Verified Correct Answers | Walden University
(2026/2027 Edition)
SUBTITLE:
50 Exam Questions with Answers & Detailed Rationales
PREPARED FOR:
[NURS 6630 Psychopharmacology - Walden University Final Examination]
DOCUMENT INCLUDES:
● Exam-style questions
● Correct answers
● Detailed rationales
● Key topics covered
TOPICS COVERED:
● Neurotransmitter Systems & Receptor Pharmacology
● Pharmacokinetics, Pharmacodynamics & Pharmacogenomics
● Antidepressants (SSRIs, SNRIs, TCAs, MAOIs, Atypical)
● Antipsychotics (Typical & Atypical)
● Mood Stabilizers (Lithium, Anticonvulsants)
● Anxiolytics, Hypnotics & Sedatives
● ADHD Pharmacotherapy
● Substance Use Disorder Treatments & Antidementia Agents
● Special Populations (Pediatrics, Geriatrics, Pregnancy)
● Adverse Effects, Drug Interactions, Monitoring & Black Box Warnings
PURPOSE:
This comprehensive final exam prep guide is designed to help NURS 6630 students
master psychopharmacological principles, understand medication mechanisms and
management, and confidently prepare for the Walden University Final Examination.
,SECTION 1: NEUROTRANSMITTER SYSTEMS & RECEPTOR PHARMACOLOGY
Question 1
A 28-year-old patient with depression is started on an SSRI. The PMHNP explains that
the primary mechanism of action involves blockade of the serotonin transporter (SERT)
at the presynaptic membrane. This action ultimately leads to which downstream effect?
A. Immediate increase in postsynaptic serotonin receptor sensitivity
B. Downregulation of 5-HT1A autoreceptors over 2-4 weeks
C. Direct agonism of D2 receptors in the mesolimbic pathway
D. Blockade of NMDA glutamate receptors in the hippocampus
Correct Answer: B
Rationale: SSRIs block SERT, increasing synaptic serotonin concentrations. Initially,
5-HT1A autoreceptors detect increased serotonin and reduce neuronal firing. Over 2-4
weeks, these autoreceptors downregulate and desensitize, allowing enhanced serotonin
neurotransmission—this delayed mechanism explains the characteristic 2-4 week
therapeutic lag. Option A is incorrect because postsynaptic receptors do not
immediately increase sensitivity; in fact, chronic SSRI use may lead to receptor
downregulation. Option C describes antipsychotic mechanisms. Option D describes
ketamine or memantine mechanisms.
Question 2
A patient taking haloperidol develops acute dystonia within 48 hours of initiation. The
PMHNP recognizes this adverse effect is due to antagonism of which receptor system?
A. 5-HT2A receptors in the prefrontal cortex
B. D2 receptors in the nigrostriatal pathway
C. H1 receptors in the tuberomammillary nucleus
D. M1 receptors in the basal ganglia
,Correct Answer: B
Rationale: Acute dystonia, along with akathisia and parkinsonism, are extrapyramidal
symptoms (EPS) caused by D2 receptor antagonism in the nigrostriatal pathway.
First-generation antipsychotics like haloperidol have high affinity for D2 receptors in this
pathway. Atypical antipsychotics have lower EPS liability due to 5-HT2A antagonism
offsetting D2 blockade. Option A is incorrect because 5-HT2A antagonism actually
reduces EPS. Option C explains sedation and weight gain. Option D explains
anticholinergic side effects.
Question 3
Which neurotransmitter system is primarily responsible for the sedating and
appetite-stimulating effects commonly seen with mirtazapine and quetiapine?
A. Dopamine D2 antagonism
B. Serotonin 5-HT2C antagonism
C. Histamine H1 antagonism
D. Norepinephrine alpha-1 antagonism
Correct Answer: C
Rationale: Histamine H1 receptor antagonism is the primary mechanism for sedation
and increased appetite/weight gain. Both mirtazapine and quetiapine are potent H1
blockers. While 5-HT2C antagonism (Option B) can increase appetite, H1 blockade is
the dominant mechanism for sedation and significantly contributes to weight gain.
Option D explains orthostatic hypotension and dizziness.
Question 4
The PMHNP is educating a patient about bupropion. Which statement accurately
describes its mechanism of action?
, A. It is a potent inhibitor of serotonin and norepinephrine reuptake
B. It acts as a norepinephrine-dopamine reuptake inhibitor (NDRI) with minimal
serotonergic activity
C. It primarily blocks alpha-2 adrenergic autoreceptors
D. It is a selective serotonin reuptake inhibitor with high affinity for the 5-HT transporter
Correct Answer: B
Rationale: Bupropion is classified as a norepinephrine-dopamine reuptake inhibitor
(NDRI). It inhibits the reuptake of norepinephrine and dopamine with minimal direct
effect on serotonin transporters. This mechanism explains why bupropion does not
cause sexual dysfunction or significant serotonergic side effects. Option A describes
SNRIs. Option C describes mirtazapine's indirect mechanism. Option D describes SSRIs.
Question 5
A patient with treatment-resistant schizophrenia is prescribed clozapine. The PMHNP
explains that clozapine's unique efficacy is attributed to its weak affinity for D2
receptors combined with potent antagonism at which receptor?
A. 5-HT1A
B. 5-HT2A
C. D1
D. GABA-A
Correct Answer: B
Rationale: Clozapine has low affinity for D2 receptors but high affinity for 5-HT2A,
5-HT2C, D1, D4, and various other receptors. The 5-HT2A/D2 ratio theory suggests that
potent 5-HT2A antagonism combined with weaker D2 antagonism contributes to its
unique efficacy in treatment-resistant schizophrenia and its lower propensity for
extrapyramidal symptoms. While clozapine also has 5-HT1A partial agonism, the
5-HT2A antagonism is central to its atypical pharmacological profile.
